NN1177 (TFA)

CAT: 0804-HY-P10032A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-P10032A-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice[1][2].
Product Name Alternative
NNC9204-1177 (TFA)
UNSPSC
12352209
Target
Cytochrome P450; GCGR; GLP Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/nn1177-tfa.html
Purity
98.66
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(NC(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@@H](C)O)=O)CCCCNC(CC[C@H](NC(CC[C@@H](C(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)CO)=O)CCC(O)=O)=O)CO)=O)=O)C(O)=O)=O)=O)CC(C)C)=O)CC(C)C)=O)CC1=CNC2=CC=CC=C12)=O)CCC(N)=O)=O)C(C)C)=O)CC3=CC=CC=C3)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C)=O)CCCNC(N)=N)=O)CCCCN)=O)CO)=O)CCC(O)=O)=O)CC(C)C)=O)CC4=CC=C(O)C=C4)=O)CCCCN)=O)CO)=O)CC(C)C)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC5=CC=CC=C5)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)(C)C)[C@@H](N)CC6=CNC=N6.OC(C(F)(F)F)=O.[x]
Molecular Formula
C206H323N51O66.xC2HF3O2
Molecular Weight
4570.07 (free base)
References & Citations
[1]Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17 (3) :e0264974.|[2]Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850.|[3]Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
Phase 1
Isoform
CYP3A4

Related Products

CatalogName
HY-P10032-01NN1177
HY-P5182A-01HsTX1 (TFA)
HY-P5601A-01Thanatin (TFA)
HY-P3037A-01Imperatoxin A (TFA)
HY-113110A-01Cysteinylglycine (TFA)
HY-P0178A-01LXW7 (TFA)
HY-50940A-01AT7519 (TFA)
HY-103536A-01Galnon (TFA)
HY-120448A-01QTX125 (TFA)
HY-156467A-01Neladalkib (TFA)

Alternative Products

CatalogName
MBS5823315NN1177
MBS3611039-01Dermorphin TFA
MBS3845905-01Diprotin A TFA
MBS3612419-01Albiglutide TFA
M21005-01Valorphin TFA
M40534-01Katacalcin TFA
M40541-01Tirzepatide TFA
M40587-01Chlorotoxin TFA
M40605-01Xenopsin TFA
M40612-01Tyroserleutide TFA

Popular Products